Immunome, Inc., was incorporated as a Pennsylvania corporation on March 2, 2006 and converted to a Delaware corporation on December 2, 2015. The company is a biotechnology company focused on the development of targeted tumor therapies. Immunome is committed to building a diverse portfolio of differentiated clinical assets to improve the quality of life of cancer patients. At the core of its strategy is expertise in the discovery, design, development, production and commercialization of antibody-drug conjugates and other oncology therapies. Immunome is advancing a R&D pipeline that includes multiple clinical and preclinical assets, demonstrating its commitment to innovation in the oncology space.
